Pharmacotherapy for Substance Use Disorders in Youths

被引:7
作者
Hammond, Christopher J. [1 ,2 ]
Gray, Kevin M. [3 ]
机构
[1] Yale Child Study Ctr, New Haven, CT USA
[2] Johns Hopkins Univ, Baltimore, MD USA
[3] Med Univ S Carolina, Charleston, SC 29425 USA
关键词
adolescence; pharmacotherapy; substance use disorders; youth; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; NICOTINE REPLACEMENT THERAPY; COGNITIVE-BEHAVIORAL THERAPY; DOUBLE-BLIND; SMOKING-CESSATION; ADOLESCENT ALCOHOLICS; CIGARETTE-SMOKING; MAJOR DEPRESSION;
D O I
10.1080/1067828X.2015.1037517
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Despite recent advances in psychosocial treatments targeting adolescent substance use disorders (SUD), effect sizes generally remain small to modest, and few treatment-enrolled youths achieve sustained abstinence. Among adults, SUD-targeted pharmacotherapies have emerged as viable options to complement psychosocial treatments and enhance outcomes. Developmental differences exist in pharmacodynamics and treatment response, and comparatively little research has focused on SUD-targeted pharmacotherapies for youths. This article provides a review and synthesis of relevant published clinical trials focusing on youth SUDs and co-occurring/comorbid psychiatric and substance use disorders. It offers recommendations for clinical practice and further research based on the limited findings to date.
引用
收藏
页码:292 / 316
页数:25
相关论文
共 89 条
[21]   Double-blind placebo-controlled trial of fluoxetine in adolescents with comorbid major depression and an alcohol use disorder [J].
Cornelius, Jack R. ;
Bukstein, Oscar G. ;
Wood, D. Scott ;
Kirisci, Levent ;
Douaihy, Antoine ;
Clark, Duncan B. .
ADDICTIVE BEHAVIORS, 2009, 34 (10) :905-909
[22]   A prospective, open-label trial of ondansetron in adolescents with alcohol dependence [J].
Dawes, MA ;
Johnson, BA ;
Ait-Daoud, N ;
Ma, JZ ;
Cornelius, JR .
ADDICTIVE BEHAVIORS, 2005, 30 (06) :1077-1085
[23]   Adolescents are not adults: Developmental considerations in alcohol users [J].
Deas, D ;
Riggs, P ;
Langenbucher, J ;
Goldman, M ;
Brown, S .
ALCOHOL-CLINICAL AND EXPERIMENTAL RESEARCH, 2000, 24 (02) :232-237
[24]   Naltrexone treatment of adolescent alcoholics: An open-label pilot study [J].
Deas, D ;
May, K ;
Randall, C ;
Johnson, N ;
Anton, R .
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2005, 15 (05) :723-728
[25]  
Deas D, 2000, HUM PSYCHOPHARM CLIN, V15, P461, DOI 10.1002/1099-1077(200008)15:6<461::AID-HUP209>3.0.CO
[26]  
2-J
[27]  
Deas D, 2009, ALCOHOL RES HEALTH, V32, P76
[28]   Early Course of Nicotine Dependence in Adolescent Smokers [J].
Doubeni, Chyke A. ;
Reed, George ;
DiFranza, Joseph R. .
PEDIATRICS, 2010, 125 (06) :1127-1133
[29]  
DuPaul GJ, 1998, ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretation
[30]   Pharmacokinetics, Safety, and Tolerability of Varenicline in Healthy Adolescent Smokers: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study [J].
Faessel, Helene ;
Ravva, Patanjali ;
Williams, Kathryn .
CLINICAL THERAPEUTICS, 2009, 31 (01) :177-189